Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

被引:88
作者
Lee, Ju-Hee
Park, Jung-Hyun
Jung, Yeonjoo
Kim, Jee-Hyun
Jong, Hyun-Soon
Kim, Tae-You
Bang, Yung-Jue
机构
[1] Seoul Natl Univ, Coll Med, Div Hematol Med Oncol, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Tumor Biol, Seoul 110744, South Korea
[3] Seoul Natl Univ, Coll Med, Natl Res Lab Canc Epigenet, Inst Canc Res, Seoul 110744, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea
关键词
D O I
10.1158/1535-7163.MCT-06-0419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thymidylate synthase (TS) overexpression is a key determinant of 5-fluorouracil (5-FU) resistance in human cancer cells. TS is also acutely up-regulated with 5-FU treatment, and, thus, novel strategies targeting TS downregulation seem to be promising in terms of modulating 5-FU resistance. Here, we report that histone deacetylase inhibitors can reverse 5-FU resistance by down-regulating TS. By using cDNA microarrays and validation experiments, we found that trichostatin A reduced the expression of both TS mRNA and TS protein. Cotreatment with trichostatin A and cycloheximide restored TS mRNA expression, suggesting that TS mRNA is repressed through new protein synthesis. On the other hand, TS protein expression was significantly reduced by lower doses of trichostatin A (50 nmol/L). Mechanistically, TS protein was found to interact with heat shock protein (Hsp) complex, and trichostatin A treatment induced chaperonic Hsp90 acetylation and subsequently enhanced Hsp70 binding to TS, which led to the proteasomal degradation of TS protein. Of note, combined treatment with low-dose trichostatin A and 5-FU enhanced 5-FU mediated cytotoxicity in 5-FU-resistant cancer cells in accordance with TS protein down-regulation. We conclude that a combinatorial approach using histone deacetylase inhibitors may be useful at overcoming 5-FU resistance.
引用
收藏
页码:3085 / 3095
页数:11
相关论文
共 50 条
[31]   Clinical significance of thymidylate synthase expression in bladder cancer [J].
Nomura, T ;
Nakagawa, M ;
Fujita, Y ;
Hanada, T ;
Mimata, H ;
Nomura, Y .
INTERNATIONAL JOURNAL OF UROLOGY, 2002, 9 (07) :368-376
[32]   Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies [J].
O'Connor, OA ;
Heaney, ML ;
Schwartz, L ;
Richardson, S ;
Willim, R ;
MacGregor-Cortelli, B ;
Curly, T ;
Moskowitz, C ;
Portlock, C ;
Horwitz, S ;
Zelenetz, AD ;
Frankel, S ;
Richon, V ;
Marks, P ;
Kelly, WK .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :166-173
[33]   Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation [J].
Park, JH ;
Jung, Y ;
Kim, TY ;
Kim, SG ;
Jong, HS ;
Lee, JW ;
Kim, DK ;
Lee, JS ;
Kim, NK ;
Kim, TY ;
Bang, YJ .
CLINICAL CANCER RESEARCH, 2004, 10 (15) :5271-5281
[34]   Prognostic importance of thymidylate synthase expression in early breast cancer [J].
Pestalozzi, BC ;
Peterson, HF ;
Gelber, RD ;
Goldhirsch, A ;
Gusterson, BA ;
Trihia, H ;
Lindtner, J ;
CortesFunes, H ;
Simmoncini, E ;
Byrne, MJ ;
Golouh, R ;
Rudenstam, CM ;
CastiglioneGertsch, M ;
Allegra, CJ ;
Johnston, PG .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1923-1931
[35]   Thymidylate synthase as an oncogene: A novel role for an essential DNA synthesis enzyme [J].
Rahman, L ;
Voeller, D ;
Rahman, M ;
Lipkowitz, S ;
Allegra, C ;
Barrett, JC ;
Kaye, FJ ;
Zajac-Kaye, M .
CANCER CELL, 2004, 5 (04) :341-351
[36]   Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer [J].
Reid, T ;
Valone, F ;
Lipera, W ;
Irwin, D ;
Paroly, W ;
Natale, R ;
Sreedharan, S ;
Keer, H ;
Lum, B ;
Scappaticci, F ;
Bhatnagar, A .
LUNG CANCER, 2004, 45 (03) :381-386
[37]   Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma [J].
Ryan, QC ;
Headlee, D ;
Acharya, M ;
Sparreboom, A ;
Trepel, JB ;
Ye, J ;
Figg, WD ;
Hwang, K ;
Chung, EJ ;
Murgo, A ;
Melillo, G ;
Elsayed, Y ;
Monga, M ;
Kalnitskiy, M ;
Zwiebel, J ;
Sausville, EA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) :3912-3922
[38]   Translational regulation as a novel mechanism for the development of cellular drug resistance [J].
Schmitz, JC ;
Liu, J ;
Lin, XK ;
Chen, TM ;
Yan, W ;
Tai, NW ;
Gollerkeri, A ;
Chu, E .
CANCER AND METASTASIS REVIEWS, 2001, 20 (1-2) :33-41
[39]  
Scott GK, 2002, MOL CANCER THER, V1, P385
[40]   New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction [J].
Shintani, Y ;
Ohta, M ;
Hirabayashi, H ;
Tanaka, H ;
Iuchi, K ;
Nakagawa, K ;
Maeda, H ;
Kido, T ;
Miyoshi, S ;
Matsuda, H .
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (06) :790-795